Global Protein Chromatography Reagents Market Outlook, 2031

Protein chromatography reagents sit at the heart of biologics manufacturing, where purification can represent 50% to 80% of total production cost. The category covers affinity resins such as Protein A, Protein G and Protein L, ion exchange, hydrophobic interaction, mixed-mode and size exclusion resins, together with the buffers, salts, detergents, elution agents, cleaning-in-place solutions and analytical reagents used to separate and characterise proteins. Protein A resin is the single most important product: it captures monoclonal antibodies from cell culture harvest at purities above 95% in one step, costs commonly in the range of USD 8,000 to 15,000 per litre, and is typically reused for 100 to 200 or more cycles to spread that cost. With more than 100 monoclonal antibodies approved in the United States alone and hundreds more in clinical development, together with fusion proteins, bispecifics, antibody-drug conjugates, vaccines, enzymes and plasma-derived proteins, demand is anchored in the expanding biopharmaceutical pipeline. Leading suppliers include Cytiva within Danaher, Merck KGaA, Thermo Fisher Scientific, Bio-Rad, Tosoh Bioscience, Purolite within Ecolab, Repligen, Sartorius, Agilent, Waters, JSR Life Sciences and Chinese entrants such as Sunresin and Bestchrom.

Several forces are reshaping the market. Biosimilars of blockbuster antibodies such as adalimumab, ustekinumab, denosumab and aflibercept have multiplied the number of commercial antibody processes, while subcutaneous reformulations, including Keytruda's subcutaneous version approved in September 2025, add new manufacturing campaigns. Process intensification, through continuous multi-column capture, higher-capacity resins with binding capacities above 60 to 80 grams per litre and alkaline-stable ligands that tolerate 0.5 molar sodium hydroxide cleaning, is reducing resin consumption per gram of antibody even as total output rises. Membrane adsorbers and pre-packed columns are gaining ground in clinical and flexible plants. Supply security has become strategic after pandemic-era shortages, prompting manufacturers to dual-source resins, and the US BIOSECURE Act, enacted in December 2025, encourages Western companies to review supply chains involving certain Chinese biotechnology firms. Industry consolidation, from Danaher's acquisition of GE's biopharma business in 2020 to Ecolab's purchase of Purolite in 2021, has concentrated supply. Laboratory and bioprocess destocking weighed on orders in 2023 and 2024 before recovering in 2025, and new modalities such as cell and gene therapies and mRNA require different chromatography solutions, broadening the reagent mix.

Drivers •Expansion of Monoclonal Antibodies and Biosimilars Monoclonal antibodies remain the largest class of biologics, and new approvals, label expansions, bispecifics, antibody-drug conjugates and the growing biosimilar market increase the number of commercial and clinical purification processes, each requiring affinity, polishing and cleaning reagents. Contract development and manufacturing organisations scale capacity to serve these programmes.

•New Modalities and Process Intensification Vaccines, gene therapy vectors, mRNA, plasma proteins, enzymes and recombinant proteins require specialised chromatography resins and buffers. Process intensification and continuous chromatography drive demand for high-capacity, alkaline-stable resins and single-use, pre-packed formats that improve productivity and flexibility.

Challenges •High Resin Costs and Process Economics Protein A and other affinity resins are expensive, and manufacturers seek to reduce cost of goods through longer resin lifetimes, higher binding capacities and alternative capture methods, which can reduce volume demand. Biosimilar price competition increases pressure on purification costs.



•Supply Concentration and Regulatory Validation A small number of suppliers dominate key resins, raising supply security concerns highlighted by past shortages. Changing resins in a validated commercial process requires regulatory filings and comparability studies, making switching difficult and slowing adoption of new products.

Trends •Alkaline-Stable, High-Capacity Affinity Resins Suppliers are launching engineered Protein A ligands that tolerate strong sodium hydroxide cleaning and offer higher dynamic binding capacity, improving resin lifetime and productivity. Affinity resins for antibody fragments, adeno-associated virus vectors and other targets are expanding the affinity toolbox.

•Continuous Chromatography, Membranes and Pre-Packed Columns Multi-column continuous capture, membrane adsorbers for polishing and virus removal, and pre-packed, single-use columns reduce buffer use, footprint and changeover time. Digital process analytics and model-based process development optimise reagent use.

Affinity resins, led by Protein A, account for the largest share of protein chromatography reagent spending because a single capture step removes most impurities from antibody harvests, and the high price per litre makes resin the costliest purification consumable. Affinity chromatography resins are the cornerstone of antibody purification. Protein A resins bind the Fc region of antibodies, enabling capture with purities often above 95% and yields above 90%, and a large commercial plant may hold several thousand litres of resin across its columns. Typical prices of USD 8,000 to 15,000 per litre make Protein A the most expensive consumable in downstream processing, which is why manufacturers track resin lifetime closely and aim for 100 to 200 or more cycles. Protein G and Protein L resins serve antibody subclasses and fragments that bind Protein A weakly, and specialised affinity ligands target antibody fragments, fusion proteins, factor VIII, adeno-associated virus vectors and other molecules. Ion exchange resins, including cation and anion exchangers based on agarose, polymethacrylate and synthetic polymer beads, are used in polishing steps to remove aggregates, host cell proteins, DNA and charge variants, and they are consumed in larger volumes but at lower prices. Hydrophobic interaction resins separate proteins by surface hydrophobicity and remove aggregates. Mixed-mode resins combine ionic and hydrophobic interactions for difficult separations. Size exclusion media are used for analytical characterisation and some polishing. Buffers, salts, detergents and elution agents, including phosphate, acetate, citrate, Tris, sodium chloride and arginine, are consumed in large quantities, with a single commercial batch using thousands of litres of buffer. Cleaning-in-place and sanitisation solutions, mainly sodium hydroxide, maintain column hygiene. Analytical reagents and columns support characterisation of glycosylation, charge variants and aggregates throughout development and release testing. Resin selection is usually locked in during early clinical development, which gives suppliers with strong process development support a lasting advantage.

Monoclonal antibodies account for the largest share of protein chromatography reagent demand because they dominate biologics sales, are produced at multi-tonne scale and follow platform purification processes built on affinity capture and ion exchange polishing. Monoclonal antibodies, including oncology, immunology, neurology and ophthalmology products and their biosimilars, consume the largest volume of protein chromatography reagents. Leading antibodies are produced in quantities of several tonnes a year, and each kilogram typically requires multiple capture and polishing cycles, so resin, buffer and cleaning chemical consumption scales directly with output. The platform approach, with Protein A capture followed by low-pH viral inactivation and one or two ion exchange or mixed-mode polishing steps, means that reagent requirements are similar across many products, favouring established suppliers. Bispecific antibodies, antibody fragments and antibody-drug conjugates often require additional polishing to remove mispaired species, unconjugated antibody and free payloads. Recombinant proteins, including insulin analogues, growth hormones, enzymes for replacement therapy, cytokines and fusion proteins, require tailored purification trains using ion exchange, hydrophobic interaction and affinity steps. Vaccines, including protein subunit vaccines, conjugate vaccines and virus-like particles, use chromatography for purification, as do viral vectors for gene therapy, where affinity resins for adeno-associated virus and anion exchange separate full and empty capsids. Plasma-derived proteins, such as immunoglobulins, albumin and clotting factors, use ion exchange and affinity steps at large scale. Industrial enzymes and food proteins use lower-cost chromatography or alternative separation methods. Research and diagnostics applications use smaller quantities of resins, columns and reagents for protein purification in laboratories, but they represent a large number of customers. GLP-1 and other peptides are mostly purified by reversed-phase chromatography with solvents rather than protein resins, so they form an adjacent rather than core segment. Antibody titres of 5 to 10 grams per litre in modern cell culture processes have increased the load on capture columns.

Commercial manufacturing accounts for the largest share of reagent consumption because large-scale production runs consume resins, buffers and cleaning solutions continuously, while process development and clinical manufacturing generate high-value demand for newer and smaller formats. Commercial manufacturing of approved biologics accounts for the largest share of protein chromatography reagent volume, as plants with bioreactors of 2,000 to 20,000 litres run campaigns throughout the year and replace resin at the end of its validated lifetime. Once a resin is written into a regulatory filing, it typically remains in use for the life of the product, giving suppliers long-term, predictable demand. Clinical manufacturing for phase 1 to phase 3 trials uses smaller columns and often pre-packed or single-use formats to support multiple programmes and fast changeovers, and it is a key stage at which resin choices become locked in for future commercial supply. Process development laboratories screen resins, buffers and conditions using high-throughput plates, miniature columns and robotic systems, consuming small volumes but influencing which products are selected. Analytical and quality control laboratories use protein chromatography columns and reagents for release testing, stability studies and characterisation of charge variants, aggregates and glycosylation. Research and academic laboratories use affinity resins, tagged-protein purification reagents such as nickel-based immobilised metal affinity media for histidine-tagged proteins, and gravity columns. Contract development and manufacturing organisations, including Lonza, Samsung Biologics, WuXi Biologics, Fujifilm Diosynth, Catalent and AGC Biologics, operate across development and commercial stages and are among the largest buyers, often standardising on preferred resins across client programmes. Continuous manufacturing facilities consume resin more intensively per litre but require smaller column volumes, changing the purchasing profile toward higher-capacity, longer-life products. Large single-use facilities and modular plants in Asia and North America favour pre-packed columns and ready-to-use buffer concentrates that reduce preparation labour and footprint.

Biopharmaceutical companies and CDMOs account for the vast majority of protein chromatography reagent purchases because they operate regulated purification processes at clinical and commercial scale, while academic, diagnostic and industrial users form smaller segments. Biopharmaceutical companies, including Roche, Amgen, Johnson & Johnson, Merck & Co., AbbVie, Sanofi, AstraZeneca, Regeneron, Novartis, Bristol Myers Squibb and many mid-sized biotechs, are the core customers, purchasing resins and reagents for their own manufacturing networks and development laboratories. Biosimilar manufacturers, including Samsung Bioepis, Celltrion, Sandoz, Biocon Biologics, Alvotech and Chinese producers, form a fast-growing customer group that is highly cost-focused and willing to evaluate alternative resins and suppliers. Contract development and manufacturing organisations represent a large and growing share of demand as drug developers outsource production, and their purchasing decisions influence resin adoption across many client projects. Vaccine manufacturers, plasma fractionators such as CSL, Grifols, Takeda and Octapharma, and gene therapy developers use chromatography reagents for their specific modalities. Academic and research institutions purchase small quantities across many laboratories, usually through distributors. Diagnostic and research reagent manufacturers purify antibodies and proteins used in test kits. Industrial enzyme and food protein producers use chromatography selectively for high-purity products. Purchasing in regulated settings emphasises lot-to-lot consistency, regulatory support files, supply assurance agreements and technical service, and large customers often hold safety stocks of critical resins equivalent to months of production. Price negotiations increasingly involve multi-year agreements tied to volume commitments. Regional suppliers in China, South Korea and India are gaining traction with domestic biopharma companies seeking lower-cost and locally sourced alternatives. Suppliers increasingly compete on regional manufacturing, technical support centres and digital ordering, and several have added resin production capacity in Asia and the United States to shorten lead times and reduce supply risk.

North America and Europe lead protein chromatography reagent consumption because of their large biopharmaceutical manufacturing bases, while Asia-Pacific, driven by China, South Korea, India and Singapore, is the fastest-growing region for biologics and biosimilar production. North America is a leading region, with the United States home to the largest number of biologics developers and manufacturing sites, major contract manufacturers and suppliers such as Thermo Fisher, Bio-Rad and Repligen, and new investment in domestic biologics production encouraged by reshoring and the BIOSECURE Act. Europe is a major region, with large antibody and vaccine manufacturing in Switzerland, Ireland, Germany, Belgium, Denmark and the Netherlands, and suppliers including Merck KGaA, Sartorius and Cytiva's European operations. Asia-Pacific is the fastest-growing region, with South Korea's Samsung Biologics and Celltrion operating some of the world's largest bioreactor capacity, China's rapidly expanding biologics and biosimilar industry and domestic resin suppliers such as Sunresin and Bestchrom gaining share, India's growing biosimilar sector led by Biocon Biologics, Japan's biopharmaceutical and resin industries including Tosoh and JSR, and Singapore's manufacturing hub. Latin America, led by Brazil and Mexico, and the Middle East and Africa have smaller but growing biologics and vaccine manufacturing activity, often supported by technology transfer agreements.


• 2025 – FDA approves subcutaneous Keytruda: Approval of a subcutaneous formulation of pembrolizumab added new manufacturing demand for one of the world's largest antibody products.
• 2025 – BIOSECURE Act enacted: The US BIOSECURE Act, included in the FY2026 National Defense Authorization Act, prompted biopharmaceutical companies to review supply chains and contract manufacturing relationships with certain Chinese biotechnology firms.
• 2025 – Bioprocessing demand recovers after destocking: Suppliers of bioprocess consumables, including chromatography resins, reported recovering orders after customers worked through excess inventory built during the pandemic.
• 2024 – Biosimilars of major antibodies launch in the United States: Biosimilars of ustekinumab and other antibodies entered the US market, increasing the number of commercial antibody purification processes.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Protein Chromatography Reagents Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Reagent Type
• Affinity Resins
• Ion Exchange Resins
• Hydrophobic Interaction Resins
• Mixed-Mode Resins
• Size Exclusion Media
• Buffers and Elution Agents
• Cleaning and Sanitization Solutions
• Analytical Reagents

By Molecule Type
• Monoclonal Antibodies
• Bispecifics and ADCs
• Recombinant Proteins
• Vaccines
• Viral Vectors
• Plasma Proteins
• Enzymes

By Scale
• Commercial Manufacturing
• Clinical Manufacturing
• Process Development
• Analytical and QC
• Research

By End User
• Biopharmaceutical Companies
• Biosimilar Manufacturers
• CDMOs
• Vaccine and Plasma Manufacturers
• Academic and Research Institutes
• Diagnostic Reagent Makers